Cognitive outcome and cyclo-oxygenase-2 gene (-765 G/C) variation in the preterm infant

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 92, Issue 2, 2007, Pages

  Harding, D R ^a,b   Humphries, S E ^c   Whitelaw, A ^a   Marlow, N ^d   Montgomery, H E ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b ST MICHAEL'S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ALLELE; ARTICLE; BRAIN DEVELOPMENT; CEREBRAL PALSY; COGNITIVE DEVELOPMENT; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE ACTIVITY; GENE INDUCTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; INFANT; MALE; MOTOR PERFORMANCE; NEWBORN; PREMATURITY; PRIORITY JOURNAL; PROMOTER REGION; RATING SCALE;

ALLELES; BIRTH WEIGHT; CEREBRAL PALSY; CHILD DEVELOPMENT; COGNITION; CYCLOOXYGENASE 2; DEVELOPMENTAL DISABILITIES; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MOTOR SKILLS; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 33947271044     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2006.099499     Document Type: Article

References (24)

1. Yoon BH, Kim CH, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1 beta, and tumor necrosis factor-a), neonatal brain white matter lesions and cerebral palsy. Am J Obstet Gynecol 1997;177:19-26.
2. Wood NS, Marlow N, Costeloe K, et al. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N Engl J Med 2000;343:378-84.
3. Stewart AL, Rifkin L, Amess PN, et al. Brain structure and neurocognitive and behavioural function in adolescents who were born very preterm. Lancet 1999;353:1653-7.
4. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992;89:4888-92.
5. Hoozemans JJ, Veerhuis R, Rozemuller AJ, et al. Neuronal COX2 expression and phosphorylation of pRb precede p38 MARK activation and neurofibrillary changes in AD temporal cortex. Neurobiol Dis 2004;15:492-9.
6. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database, Syst Rev 2002; (3):CD000174. DOI: 10, 1002/14651858.CD000174..
7. Hammerman C, Glaser J, Schimmel MS, et al. Continuous versus multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity. Pediatrics 1995;95:244-8.
8. Cipollone F, Fazia M, Iezzi A, et al. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 2004;24:1259- 65.
9. Nakayama M, Uchimura K, Zhu RL, et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 1998;95:10954-9.
10. McCullough L, Wu L, Haughey N, et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004;24:257-68.
11. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22:1631-6.
12. Cipollone F, Toniato E, Martinotti S, et al. Identification of new elements of plaque stability (INES) study group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004;291:2221-8.
13. Investigators for the Avon Premature Infant Project. Randomised trial of parental support for families with very preterm children. Arch Dis Child Fetal Neonatal Ed 998;79:F4-11.
14. Harding DR, Dhamrait S, Whitelaw A, et al. Does interleukin-6 genotype influence cerebral injury or developmental progress after preterm birth? Pediatrics 2004;114:941-7.
15. Day IN, Humphries SE, Richards S, et al. High-throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). Biotechniques 1995;19:830-5.
16. Griffiths R. The abilities of young children. Amersham, England: Association for Child Development, 1954.
17. Elliot CD, Murray DJ, Pearlson LS. The British Ability Scales. Windsor: NFER-Nelsan Publishing, 1983.
18. Henderson SE, Sugden DA. Movement assessment battery for children. London: The Psychological Corporation, 1992.
19. Oxford Health Authority/National Perinatal Epidemiology Unit. Report of two working groups. Disability and Perinatal Care: Measurement of health status at two years. Oxford, UK: Oxford Health Aauthority/National Perinatal Epidemiology Unit, 1994.
20. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-8.
21. Brooks-Gunn J, McCarton CM, Casey PH, et al. Early intervention in low-birth-weight premature infants. Results through age 5 years from the Infant Health and Development Program. JAMA 1994;272: 1257-62.
22. Bilak M, Wu L, Wang Q, et al. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol 2004;56:240-8.
23. Marlow N, Wolke D, Bracewell MA, et al. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005;352:9-19.
24. Harding D, Brull D, Humphries S, et al. Variation in the interleukin-6 gene is associated with impaired cognitive development in children born prematurely: a preliminary study. Pediatr Res 2005;58:117- 20.